Abstract Context Prostate cancer (PCa) is one of the most common cancers worldwide.
Understanding the epidemiology and risk factors of the disease is paramount to improve …

Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Importance Hereditary factors play a key role in the risk of developing several cancers.
Identification of a germline predisposition can have important implications for treatment …

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment,
management, and hereditary cancer assessment. Critical needs include optimized …

Complex rearrangement patterns and mitotic errors are hallmarks of most pancreatic ductal
adenocarcinomas (PDAC), a disease with dismal prognosis despite some therapeutic …

Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most
common cause of cancer-related deaths in men. Family history of PCa, hereditary breast …

Despite survival improvements achieved over the last two decades, prostate cancer remains
lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches …

The treatment landscape of metastatic prostate cancer has evolved significantly over the
past two decades. Several landmark phase 3 trials led to new drug approvals and rapid …